Moreover, treatment with the HER2-specific tyrosine kinase inhibitors (AG285 and HER2 siRNA) was found to produce a down-regulation of the E-cad in ovarian cancer cells [36]. The gene discussed is CDH1; the disease is ovarian cancer.